TAK-063
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 510331

CAS#: 1238697-26-1

Description: TAK-063, also known as Balipodect., is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. TAK-063 represents a promising drug for the treatment of schizophrenia with potential for superior safety and tolerability profiles.


Chemical Structure

img
TAK-063
CAS# 1238697-26-1

Theoretical Analysis

MedKoo Cat#: 510331
Name: TAK-063
CAS#: 1238697-26-1
Chemical Formula: C23H17FN6O2
Exact Mass: 428.1397
Molecular Weight: 428.42
Elemental Analysis: C, 64.48; H, 4.00; F, 4.43; N, 19.62; O, 7.47

Price and Availability

Size Price Availability Quantity
10.0mg USD 90.0 Ready to ship
25.0mg USD 150.0 Ready to ship
50.0mg USD 250.0 Ready to ship
100.0mg USD 450.0 Ready to ship
200.0mg USD 750.0 Ready to ship
500.0mg USD 1450.0 Ready to ship
1.0g USD 2250.0 Ready to ship
2.0g USD 3950.0 2 Weeks
5.0g USD 6950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: TAK063, TAK 063, TAK-063, Balipodect

IUPAC/Chemical Name: 1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one

InChi Key: KVHRYLNQDWXAGI-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H17FN6O2/c1-32-21-15-29(19-9-8-17(14-18(19)24)28-13-5-11-25-28)27-22(23(21)31)20-10-12-26-30(20)16-6-3-2-4-7-16/h2-15H,1H3

SMILES Code: O=C1C(C2=CC=NN2C3=CC=CC=C3)=NN(C4=CC=C(N5N=CC=C5)C=C4F)C=C1OC

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: Balipodect (TAK-063) is a PDE10A inhibitor with IC50 of 0.30 nM; >15000-fold selectivity over other PDEs.
In vitro activity: The half-maximal inhibitory concentration (IC50) value of TAK-063 for PDE10A2 was 0.30 nM, and the minimum IC50 value among the other 10 PDE families was 5500 nM for PDE4D2. Thus, the PDE10A2 selectivity of TAK-063 over other PDE family enzymes was more than 15000-fold. In vitro PDE10A2 selectivity of TAK-063 was further assessed by measuring its inhibitory or stimulatory activities against enzymes (Table 1) and receptors (Table 2) at Ricerca Biosciences (Concord, OH). More than 50% inhibition or stimulation by 10 μM of TAK-063 was considered as a significant response. TAK-063 did not induce a significant response in 91 target molecules, except for PDEs. These results indicate that TAK-063 is a potent and selective inhibitor of human PDE10A in vitro. Reference: PLoS One. 2015; 10(3): e0122197. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376699/
In vivo activity: TAK-063 showed significant improvement in overall recovery, with a difference in stroke + 3.0 mg/kg over the 9-week treatment compared with stroke + vehicle controls (Fig. 1a, n = 8–10 for each treatment group, P = 0.0129). TAK-063 did not enhance recovery of motor function in cortical stroke (Fig. 1b, n = 8–11, P = 0.9934). Overall, the results obtained from the Grid-Walking Task indicate that a daily dose of TAK-063 leads to improvement in gait and forelimb motor control in striatal stroke but not in cortical stroke. A separate behavioral test, the Cylinder Task, a measure of forelimb use in exploratory rearing, was also performed for both striatal and cortical stroke mice. The Cylinder test showed great variability between animals in motor performance and across time points. The stroke + 3.0 mg/kg dose of TAK-063 produced a tendency toward recovery of function in the affected forelimb in the striatal stroke over the 9-week treatment compared with stroke + vehicle controls (Supplementary Fig. 2A, P = 0.0558). Reference: Transl Stroke Res. 2021; 12(2): 303–315. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644574/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 55.0 128.38

Preparing Stock Solutions

The following data is based on the product molecular weight 428.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Harada A, Suzuki K, Kamiguchi N, Miyamoto M, Tohyama K, Nakashima K, Taniguchi T, Kimura H. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor. PLoS One. 2015 Mar 27;10(3):e0122197. doi: 10.1371/journal.pone.0122197. PMID: 25815469; PMCID: PMC4376699. 2. Birjandi SZ, Abduljawad N, Nair S, Dehghani M, Suzuki K, Kimura H, Carmichael ST. Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type. Transl Stroke Res. 2021 Apr;12(2):303-315. doi: 10.1007/s12975-020-00819-8. Epub 2020 May 6. Erratum in: Transl Stroke Res. 2020 Oct 29;: PMID: 32378029; PMCID: PMC7644574. 3. Tohyama K, Sudo M, Morohashi A, Kato S, Takahashi J, Tagawa Y. Pre-clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK-063. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):577-587. doi: 10.1111/bcpt.12964. Epub 2018 Feb 26. PMID: 29345044.
In vitro protocol: 1. Harada A, Suzuki K, Kamiguchi N, Miyamoto M, Tohyama K, Nakashima K, Taniguchi T, Kimura H. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor. PLoS One. 2015 Mar 27;10(3):e0122197. doi: 10.1371/journal.pone.0122197. PMID: 25815469; PMCID: PMC4376699.
In vivo protocol: 1. Birjandi SZ, Abduljawad N, Nair S, Dehghani M, Suzuki K, Kimura H, Carmichael ST. Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type. Transl Stroke Res. 2021 Apr;12(2):303-315. doi: 10.1007/s12975-020-00819-8. Epub 2020 May 6. Erratum in: Transl Stroke Res. 2020 Oct 29;: PMID: 32378029; PMCID: PMC7644574. 2. Tohyama K, Sudo M, Morohashi A, Kato S, Takahashi J, Tagawa Y. Pre-clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK-063. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):577-587. doi: 10.1111/bcpt.12964. Epub 2018 Feb 26. PMID: 29345044.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x
Knott EP, Assi M, Rao SN, Ghosh M, Pearse DD. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair. Int J Mol Sci. 2017 Mar 24;18(4):696. doi: 10.3390/ijms18040696. PMID: 28338622; PMCID: PMC5412282.

1: Suzuki K, Harada A, Shiraishi E, Kimura H. In Vivo Pharmacological Characterization of TAK-063, a Potent and Selective Phosphodiesterase 10A Inhibitor with Antipsychotic-Like Activity in Rodents. J Pharmacol Exp Ther. 2015 Mar;352(3):471-9. doi: 10.1124/jpet.114.218552. Epub 2014 Dec 18. PubMed PMID: 25525190.

2: Kunitomo J, Yoshikawa M, Fushimi M, Kawada A, Quinn JF, Oki H, Kokubo H, Kondo M, Nakashima K, Kamiguchi N, Suzuki K, Kimura H, Taniguchi T. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyri dazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. J Med Chem. 2014 Nov 26;57(22):9627-43. doi: 10.1021/jm5013648. Epub 2014 Nov 10. PubMed PMID: 25384088.

TAK-063

10.0mg / USD 90.0